NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (257)	1/17/1998 6:56:00 PM
From: james	Read Replies (2) of 328

TD, thx. I noticed nxtr while reading some old papers in pnas pnas.org. nxtr's selex is a very potent tech, at least to me, only deal with <100k libraries. A zillion compounds round/target (10E14--10E15). Way behond the whole combine of all the big-pharms' compound libraries (<1 mil each for the top-50), though these are oligos. But for extra-cellular targets.........I've to think about this one hard. Any good news, this one (& isip) might get into the classical short squeeze. regards

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next